Lineage Cell Therapeutics, Inc. (LCTX)
The price, the headline numbers and the latest news, in one place.
Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, Analysis & Data
| Bid | 1.07 |
| Market Cap | 278M |
| Revenue (ttm) | 13.1M |
| Net Income (ttm) | -32.3M |
| 1.55 | |
| -0.19 | |
| n/a | |
| -10.78 | |
| P/B (ttm) | 4.56 |
| P/S (ttm) | 21.26 |
| Earnings Date | Mar 5, 2026 |
| Ask | 1.22 |
| Volume | 916,481 |
| Avg. Volume (20D) | 1,332,828 |
| Open | 1.11 |
| Previous Close | 1.11 |
| Day's Range | 1.09 - 1.12 |
| 52-Week Range | 1.00 - 2.09 |
| Analyst | n/a |
| Price Target | 4.5 (309.09%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that ...
Financial Performance
In 2025, Lineage Cell Therapeutics's revenue was 14.56M, an increase of 53.24% compared to the previous year's 9.5M. Earnings were -63.53M, an increase of 241.41%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for LCTX stock is "null". The 12-month stock price forecast is 4.5, which is upside of 309.09% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.07M misses estimates by $0, with -61.34% YoY decline.
- EPS of 0.01 exceeds estimates by 0.04, with 200.00% YoY growth.
Analysts project revenue of ... Upgrade
